Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 7/20 | 0.53 |
| ▸ | BRAF | P15056 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705288 | 0.93 | MAPK14 (0.57) | MAPK14RAF1BRAF | |
| SCHEMBL1705078 | 0.85 | MAPK14 (0.49) | MAPK14RAF1BRAF | |
| SCHEMBL10158066 | 0.84 | RAF1 (0.49) | MAPK14RAF1BRAF | |
| SCHEMBL5113465 | 0.81 | MAPK14 (1.00) | MAPK14LCKMAP2K1CSF1RKDR | |
| SCHEMBL1705565 | 0.80 | LCK (0.65) | MAPK14LCKCSF1RKDRRAF1 | |
| SCHEMBL1704008 | 0.78 | MAPK14 (0.44) | MAPK14LCKKDRRAF1BRAF | |
| SCHEMBL10159643 | 0.77 | TRPV1 (0.48) | MAPK14LCKKDR | |
| SCHEMBL1704606 | 0.77 | ABL1 (0.49) | MAPK14CSF1RRAF1 | |
| SCHEMBL1705324 | 0.77 | ABL1 (0.43) | MAPK14 | |
| SCHEMBL2975048 | 0.76 | MAPK14 (0.64) | MAPK14LCKMAP2K1CSF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010144909-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | OAT, OTC, DLD | MAPK14 4759/4885LCK 1107/4885MAP2K1 4692/4885 |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | GOT2, OAT, ABAT | MAPK14 4735/4885LCK 290/4885MAP2K1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.